Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of enhancing an immune response to an antigen comprising administering an effective amount of an agent that can augment the level of a TAP molecule in a target cell bearing the antigen to a cell or animal in need thereof wherein the agent is a nucleic acid sequence comprising a sequence encoding a TAP molecule and wherein administration of the agent enhances the immune response to the antigen.

2. (Canceled) A method according to claim 1 wherein the agent is a nucleic acid sequence comprising a sequence encoding a TAP molecule.

3. (Original) A method according to claim 1 wherein the target cell is a virally infected cell.

4. (Original) A method according to claim 1 wherein the target cell is a tumor cell.

5. (Currently amended) A method according to claim 1 ~~2~~ wherein the TAP molecule comprises TAP-1.

6. (Currently amended) A method according to claim 1 ~~2~~ wherein the TAP molecule comprises TAP-2.

7. (Currently amended) A method according to claim 1 ~~2~~ further comprising administering a nucleic acid sequence encoding an antigen.

8. (Original) A method according to claim 7 wherein the antigen is a viral antigen.

9. (Original) A method according to claim 7 wherein the antigen is a tumor antigen.

10. (Currently Amended) A method according to claim 1 ~~2~~ further comprising administering a growth factor, chemokine , accessory molecule or a gene inducible by retinoic acid, tumor necrosis factor, interferon alpha, beta or gamma, tapasin, calnexin, calreticulin, p53, p58, MHC I heavy chain, HSP 70, HSP 90, BIP, GRB94, interferon response proteins 3 and 7.

11. (Original) A method according to claim 10 wherein the accessory molecule is selected from the group consisting of tapasin, calnexin, calreticulin, p58, MHC class I heavy chain, β_2M, LMP2 and LMP7.

12. (Original) A method according to claim 4 wherein the animal is also subjected to surgery, radiation, chemotherapy, immunotherapy or photodynamic therapy.

13. (Canceled) A method according to claim 1 wherein the agent is interferon-γ.

14. (Original) A method according to claim 1 wherein the agent is administered intraperitoneally, subcutaneously, intravenously, orally, mucosally, submucosally or intradermally.

15. (Original) A method according to claim 4 wherein the agent is administered intraperitoneally, intratumorally, subcutaneously, intravenously, orally, mucosally, submucosally or intradermally.

16. (Original) A method according to claim 1 ~~2~~ wherein the nucleic acid molecule is in a vector.

17. (Original) A method according to claim 16 wherein the vector is a viral vector.

18. (Original) A method according to claim 17 wherein the viral vector is selected from the group consisting of vaccinia based vectors, adenovirus based vectors, lenti virus based vectors and HSV based vectors .

19. (Original) A method according to claim 16 wherein the vector is a plasmid.

20. (Currently amended) A method according to claim 19 wherein the plasmid is ~~ian~~ a liposome formulation.